Company Overview and News
Calumet Specialty Products Partners (CLMT), an MLP involved in the production of specialty fuels and other refined products, was the top MLP gainer in the week ending June 1. Calumet Specialty Products Partners rallied 23.9%. Last week, the gains could have been due to strong refined products demand during Memorial Day weekend and the start of the summer driving season. Calumet Specialty Products Partners has traded in the green for 2018 following last week’s rally.
NGL LGCYP LGCYO CLMT NGL.PRB ENLK ENLC CEQP NS.PRC NS.PRB NSH LGCY CVRR ENBL NS NS.PRA
It's a perennial favorite, with investors and industry insiders requesting it over and over again. We wanted to provide a simple number that could be referenced and compared. Something like the GDP growth rate, which on its face is a quick look at the economy, but in reality, is a simplified summary of a nuanced subject.
LINEQ ETP.PRC LGCYP LGCYO BBPPQ LNGG VNRR BBEP WPZ ETP VNR LGCY VNRAP VNRBP VNRCP BBEPQ EEP PAA BBEPP LINE
Legacy Reserves (LGCY), the upstream MLP involved in crude oil, natural gas, and NGLs (natural gas liquids) production, was the top MLP loss last week. Legacy Reserves fell 36.2% mainly due to the weakness in crude oil prices. Although Legacy Reserves has fallen significantly from its YTD highs, it’s still up 217.4% in 2018. The stock might continue to see high volatility in the near term due to strong movements in crude oil prices.
CCLP LGCYP SDLP LGCYO AMID LGCY SDRL SXE PAA BPL HCLP SNMP
Legacy Reserves (LGCY), an upstream MLP involved in crude oil, natural gas, and NGLs (natural gas liquids) production, was upgraded by UBS in the week ending May 18. UBS upgraded Legacy Reserves to “neutral,” which is equivalent to a “hold” from “sell.” UBS increased Legacy Reserves’ target price to $8 from $1.5. Currently, only one analyst has coverage on Legacy Reserves. The partnership is trading above its target price.
LGCYP TCP LGCYO GMLP HMLP GLOP.PRA GLOP.PRB LGCY GLOP HMLP.PRA TEP
In this part, we’ll discuss the top percentage gainers from the upstream sector in the US for the week starting on May 14. To compile the list of the top upstream gainers, we only used oil and gas producers with market capitalizations greater than $100 million and an average trading volume greater than 100,000 shares last week.
CKRGZ LGCYP LGCYO CHKVP CRK CHKDH CHKVZ CHKDG CHKWZ CHKDJ EGC CHKDP CHK.WI CHK LGCY CHK.PRD
The three only mark an acceleration of the trend of MLP "roll-ups," however. Many others have been announced in 2018.
ARLP LGCYP APLP LGCYO CQP EBGUF RMP AROC ENB TEP TEGP SEP NSH EQM WPZ WMB EQGP EEP LNG BWP L ENB ENF LGCY
SunCoke Energy Partners (SXCP), an MLP involved in coke manufacturing and logistics, was the top MLP loss in the week ending April 27. The partnership had weak earnings in 1Q18. The partnership posted an adjusted EBITDA of $49.5 million during 1Q18—compared to $51.7 million in 1Q17 The YoY decline was mainly driven by planned outage and maintenance costs in the partnership’s Domestic Coke segment. However, the partnership reaffirmed its 2018 adjusted EBITDA guidance of $215 million–$225 million.
LGCYP LGCYO TLP GLOP.PRA SXCP GLOP.PRB GLOP TEP TEGP UAN EQM CAPL LGCY NRP
Navios Maritime Midstream Partners (NAP), an MLP involved in the marine transportation of crude oil, refined products, and NGLs, was the top MLP gainer in the week ending April 20. Navios Maritime Partners rallied 29.2% due to J.P. Morgan upgrading it to a “buy.” Overall, the partnership has lost 55.4% since the beginning of 2018. The fall could mainly be attributed to the partnership’s weak operating performance in 4Q17.
NGL LGCYP SDLP LGCYO NGL.PRB MMLP NAP BHI TCP DKL DMLP LGCY SDRL FGP NMM
21h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET